Dalbavancin Bioglan

What Is Dalbavancin Bioglan and What Is It Used For?

Dalbavancin Bioglan is a lipoglycopeptide antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) in adults. It is effective against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and is administered as an intravenous infusion.

Dalbavancin belongs to the lipoglycopeptide class of antibiotics, which are structurally related to vancomycin but engineered to have enhanced potency and a dramatically longer duration of action. The active ingredient, dalbavancin, is a semi-synthetic derivative of the naturally occurring glycopeptide A-40926. It was designed to overcome some of the limitations of older glycopeptide antibiotics, particularly their requirement for frequent dosing and limited tissue penetration.

The primary indication for dalbavancin is the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. This category of infections encompasses a range of conditions that involve the skin, subcutaneous tissue, fascia, or muscle. Common presentations include cellulitis and erysipelas (characterized by spreading redness, warmth, and swelling of the skin), wound infections (including surgical site infections and traumatic wounds that become infected), and major cutaneous abscesses (collections of pus within the deeper layers of the skin).

Dalbavancin exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. Specifically, it binds with high affinity to the D-alanyl-D-alanine terminus of the peptidoglycan stem pentapeptide in the growing cell wall. This binding prevents two critical enzymatic reactions: transglycosylation (the formation of long glycan chains) and transpeptidation (the cross-linking of these chains). Without a properly constructed cell wall, the bacterium cannot maintain its structural integrity and ultimately undergoes lysis and death.

What sets dalbavancin apart from other antibiotics in its class is its remarkably long half-life of approximately 346 hours (roughly 14 days). This extended duration of action is attributed to its lipophilic side chain, which promotes strong binding to plasma proteins (approximately 93% protein-bound) and facilitates slow redistribution from tissues. This pharmacokinetic property allows dalbavancin to be administered as either a single 1500 mg intravenous dose or as a two-dose regimen (1000 mg on day 1, followed by 500 mg on day 8), providing a full treatment course in just one or two clinic visits.

Spectrum of activity

Dalbavancin demonstrates potent in vitro activity against a broad range of clinically relevant Gram-positive organisms. These include Staphylococcus aureus (both methicillin-susceptible [MSSA] and methicillin-resistant [MRSA] strains), Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalactiae (Group B Streptococcus), the Streptococcus anginosus group, and Enterococcus faecalis (vancomycin-susceptible strains only). It is not active against Gram-negative bacteria or vancomycin-resistant enterococci (VRE) possessing the vanA gene.

Clinical trial evidence

The efficacy of dalbavancin in treating ABSSSI has been established through pivotal Phase III clinical trials, including the DISCOVER 1 and DISCOVER 2 studies. In these double-blind, randomized, non-inferiority trials, dalbavancin demonstrated clinical outcomes comparable to vancomycin followed by oral linezolid. The early clinical response rates at 48 to 72 hours (the primary endpoint required by regulatory agencies) were similar between treatment groups, confirming dalbavancin's effectiveness in this patient population.

What Should You Know Before Taking Dalbavancin Bioglan?

Before receiving dalbavancin, inform your doctor about any allergies (especially to glycopeptide antibiotics like vancomycin), liver or kidney disease, pregnancy or breastfeeding, and all medications you are currently taking. Dalbavancin is contraindicated in patients with known hypersensitivity to dalbavancin or any of its excipients.

Contraindications

Dalbavancin is contraindicated in patients with known hypersensitivity to dalbavancin or to any of the excipients in the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported with glycopeptide antibiotics, and cross-sensitivity between members of this class is possible. If a patient has a documented history of serious allergic reaction to vancomycin or teicoplanin, dalbavancin should be used with extreme caution, and the prescriber must weigh the benefits against the potential risks.

There are no absolute contraindications based on age alone, but the safety and efficacy of dalbavancin have not been established in patients under 18 years of age. Pediatric use is therefore not currently recommended outside of clinical trials or when no suitable alternatives exist.

Warnings and Precautions

Several important precautions should be considered before and during treatment with dalbavancin:

• Infusion-related reactions: Rapid intravenous infusion of glycopeptide antibiotics can cause "red man syndrome," characterized by flushing of the upper body, urticaria, pruritus, and sometimes hypotension. To minimize this risk, dalbavancin should be infused over at least 30 minutes. If an infusion-related reaction occurs, the infusion rate should be slowed or temporarily stopped.
• Clostridioides difficile-associated diarrhea (CDAD): As with virtually all antibiotics, dalbavancin use carries a risk of Clostridioides difficile infection, which can range from mild diarrhea to severe, life-threatening pseudomembranous colitis. Patients who develop diarrhea during or after treatment should be evaluated for CDAD.
• Hepatic impairment: Caution is advised in patients with moderate hepatic impairment (Child-Pugh Class B). Dose adjustment may be necessary, and liver function should be monitored. There is limited data in patients with severe hepatic impairment (Child-Pugh Class C), and use in this population is not recommended unless no suitable alternative exists.
• Renal impairment: For patients with chronic renal impairment not receiving regular hemodialysis and with creatinine clearance below 30 mL/min, the recommended dose should be reduced. No dose adjustment is required for patients on regular hemodialysis.
• Superinfection: Prolonged use or use in the absence of a confirmed susceptible bacterial infection may lead to superinfection with resistant organisms, including fungi. If superinfection occurs, appropriate measures should be taken.
• Laboratory monitoring: Dalbavancin may interfere with certain coagulation tests, particularly the prothrombin time (PT) and international normalized ratio (INR), producing falsely elevated values. This interference is most pronounced when blood samples are drawn within the first few days after infusion.

Pregnancy and Breastfeeding

There is limited clinical data on the use of dalbavancin during pregnancy. Animal reproductive toxicology studies (conducted in rats and rabbits) did not reveal evidence of teratogenicity at clinically relevant doses. However, given the lack of controlled studies in pregnant women, dalbavancin should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus. Women of childbearing potential should discuss contraception with their prescribing physician.

It is not known whether dalbavancin is excreted in human breast milk. Given its high molecular weight and extensive protein binding, significant transfer into breast milk is considered unlikely, but caution is nonetheless advised. The decision to continue or discontinue breastfeeding during dalbavancin therapy should take into account the benefit of breastfeeding to the child and the benefit of treatment to the mother.

How Does Dalbavancin Bioglan Interact with Other Drugs?

Dalbavancin has relatively few clinically significant drug interactions. However, it may interfere with coagulation tests (INR/PT) and should be used cautiously with other nephrotoxic or ototoxic drugs. Inform your doctor about all medications you are taking, including prescription drugs, over-the-counter medicines, and supplements.

Compared to many other antibiotics, dalbavancin has a relatively favorable drug interaction profile. It is not metabolized by cytochrome P450 enzymes and does not significantly inhibit or induce common CYP isoforms. Nevertheless, several potential interactions merit attention in clinical practice.

Major Interactions

The most clinically significant interaction involves dalbavancin's effect on coagulation laboratory tests. Dalbavancin can bind to and interfere with the phospholipid reagents used in PT/INR assays, leading to falsely elevated results. This does not represent an actual anticoagulant effect; the patient's in vivo coagulation is unaffected. However, clinicians who are unaware of this interaction may inappropriately withhold anticoagulation therapy or perform unnecessary dose adjustments. To mitigate this, coagulation tests should ideally be drawn just prior to the next dalbavancin dose (when drug levels are at their lowest) or alternative assays should be used.

When used concomitantly with other nephrotoxic agents such as aminoglycoside antibiotics, amphotericin B, or ciclosporin, there is a theoretical risk of additive nephrotoxicity. While dalbavancin itself has a relatively low intrinsic nephrotoxic potential compared to vancomycin, the long persistence of the drug in the body means that renal monitoring should continue for an extended period when such combinations are used.

Minor Interactions

In vitro studies have shown that dalbavancin does not significantly inhibit or induce the major cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4). This means that dalbavancin is unlikely to alter the plasma concentrations of drugs metabolized through these pathways. Similarly, dalbavancin is not a substrate for P-glycoprotein and is unlikely to be affected by P-gp inhibitors or inducers.

No clinically significant interactions have been observed with commonly co-prescribed medications such as metformin, midazolam, or oral contraceptives in dedicated drug-drug interaction studies. However, as dalbavancin remains in the body for an extended period, patients should always inform their healthcare provider about all medications they are taking, including herbal supplements and over-the-counter products.

What Is the Correct Dosage of Dalbavancin Bioglan?

The recommended adult dose is either a single 1500 mg intravenous infusion or 1000 mg on day 1 followed by 500 mg on day 8. Each dose is infused over 30 minutes. Dose adjustments are needed for patients with significant renal or hepatic impairment.

Dalbavancin is exclusively administered as an intravenous infusion and must be prepared by a qualified healthcare professional. The powder for concentrate for solution for infusion is reconstituted and then further diluted prior to administration. It must never be administered as an intravenous bolus injection.

Adults

Children

The safety and efficacy of dalbavancin in pediatric patients (under 18 years of age) have not yet been established. Clinical data in this population are limited, and dalbavancin is not currently approved for use in children. Ongoing clinical trials are evaluating its potential use in adolescents and younger children, but until such data are available, dalbavancin should not be used in pediatric patients outside of clinical research settings.

Elderly

No dose adjustment is required based on age alone. In clinical trials, elderly patients (65 years and older) showed similar pharmacokinetic profiles and clinical outcomes compared to younger adults. However, elderly patients more frequently have reduced renal function, and dose adjustments should be made according to creatinine clearance levels as outlined above. Age-related hepatic impairment should also be considered.

Missed Dose

If a patient misses the scheduled Day 8 dose in the two-dose regimen, it should be administered as soon as possible. The clinical significance of a delayed second dose has not been formally studied, but given dalbavancin's long half-life, a brief delay (a few days) is unlikely to result in subtherapeutic drug levels. However, patients should contact their healthcare provider to reschedule the infusion promptly. Under no circumstances should two doses be administered simultaneously or in close succession to compensate for a missed dose.

Overdose

There is limited clinical experience with dalbavancin overdose. In Phase I clinical trials, single doses up to 1500 mg were administered without dose-limiting toxicity. In the event of accidental overdose, the patient should be monitored for signs and symptoms of adverse effects, and supportive care should be initiated as clinically indicated. Dalbavancin is not significantly removed by hemodialysis (less than 6% of a dose is eliminated during a 3-hour dialysis session), so dialysis is not expected to be an effective means of drug removal.

What Are the Side Effects of Dalbavancin Bioglan?

The most common side effects of dalbavancin include nausea, headache, diarrhea, and infusion-site reactions. Uncommon effects include rash, pruritus, vomiting, and elevated liver enzymes. Serious but rare adverse events include anaphylaxis and Clostridioides difficile-associated diarrhea.

Like all medications, dalbavancin can cause side effects, although not everyone experiences them. In clinical trials, dalbavancin was generally well tolerated, with most adverse events being mild to moderate in severity and self-limiting. The overall discontinuation rate due to adverse events was low (approximately 2-3%).

The side effects are classified below by frequency, according to the standard convention used in clinical pharmacology:

Infusion-related reactions

As with other glycopeptide antibiotics, rapid intravenous administration of dalbavancin can trigger histamine-mediated reactions, colloquially known as "red man syndrome." This phenomenon is characterized by flushing of the face, neck, and upper torso, sometimes accompanied by pruritus, urticaria, and rarely hypotension. To minimize the risk, dalbavancin must be infused over a minimum of 30 minutes. If a reaction occurs, the infusion should be slowed or temporarily paused until symptoms resolve. This reaction is not a true allergy but rather a pharmacological effect related to infusion speed.

Long-term considerations

Given the extended half-life of dalbavancin, it is important to recognize that adverse effects may manifest or persist for a longer period than with conventional antibiotics. Patients should be counseled to remain vigilant for signs and symptoms of adverse reactions for at least two to three weeks after receiving their last dose. Similarly, clinicians should consider the prolonged drug exposure when evaluating new symptoms that develop days or even weeks after infusion.

How Should You Store Dalbavancin Bioglan?

Store the unopened vials below 25°C (77°F). Do not freeze. The reconstituted solution may be stored at 2-8°C for up to 48 hours. The diluted infusion solution should be used within 48 hours if stored in a refrigerator (2-8°C) or within 24 hours at room temperature.

Proper storage of dalbavancin is essential to maintain the stability and potency of the medication. As a powder for concentrate for solution for infusion, the vial has specific storage requirements at each stage of preparation:

• Unopened vials: Store at temperatures not exceeding 25°C (77°F). Keep the vials in the original carton to protect from light. Do not freeze.
• Reconstituted solution: After reconstitution with sterile water for injection, the resulting concentrate may be stored in the vial for up to 48 hours at 2-8°C (36-46°F). Do not freeze the reconstituted solution.
• Diluted infusion solution: After dilution with 5% dextrose (glucose) solution to the appropriate infusion volume, the solution should be used within 48 hours if stored at 2-8°C or within 24 hours if stored at room temperature (up to 25°C). From a microbiological standpoint, the solution should ideally be used immediately after preparation.

The reconstituted and diluted solution should be a clear, colorless to pale yellow liquid. If particulate matter or discoloration is observed, the solution must not be used. The reconstituted solution should not be mixed with other medications in the same infusion bag or infusion line. If a common intravenous line is used to administer other drugs, the line should be flushed with 5% dextrose solution before and after dalbavancin infusion.

Do not use dalbavancin after the expiry date stated on the carton and vial label after "EXP." The expiry date refers to the last day of that month. Keep this and all medications out of the sight and reach of children. Do not dispose of medications via wastewater or household waste; consult your pharmacist about proper disposal methods.

What Does Dalbavancin Bioglan Contain?

Each vial contains 500 mg of dalbavancin (as dalbavancin hydrochloride). Excipients include mannitol, lactose monohydrate, hydrochloric acid, and sodium hydroxide (for pH adjustment). The powder is white to off-white and is reconstituted prior to intravenous infusion.

Understanding the composition of a medication is important for identifying potential allergens and understanding the formulation characteristics. Dalbavancin Bioglan is presented as a sterile, lyophilized (freeze-dried) powder that requires reconstitution before use.

Active ingredient

The active substance is dalbavancin, present as dalbavancin hydrochloride. Each vial contains dalbavancin hydrochloride equivalent to 500 mg of dalbavancin free base. Dalbavancin is a semi-synthetic lipoglycopeptide antibiotic with a molecular weight of approximately 1817 Da. Its chemical structure features a heptapeptide core (similar to vancomycin and teicoplanin) with a lipophilic side chain that contributes to its extended half-life and enhanced binding to the bacterial cell membrane.

Excipients (inactive ingredients)

• Mannitol (E421): Used as a bulking agent to provide a stable lyophilized cake and facilitate reconstitution.
• Lactose monohydrate: Used as a stabilizer. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should be aware of this excipient. The amount of lactose per vial is small but should be noted.
• Hydrochloric acid: Used for pH adjustment during manufacturing.
• Sodium hydroxide: Used for pH adjustment during manufacturing.

The pH of the reconstituted solution is approximately 3.5 to 4.5. The osmolality of the final diluted infusion solution depends on the volume of diluent used and is designed to be suitable for intravenous administration. The product does not contain preservatives, so aseptic technique must be maintained during preparation and handling.